Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU
Real World Data Played A Key Role In The Drug’s Initial Approval
MolMed decided to the withdraw the drug's conditional marketing authorization after Phase III clinical trial results showed that the drug offered no benefit on disease-free survival.
